2021-2030 Analysis and Review Chloroquine Products Market
Chloroquine Products Market By Clinical Application (Protozoan Infection, Autoimmune Diseases and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The chloroquine products market was valued at USD 510.1 Mn by 2019. The rising prevalence of protozoan infection worldwide primarily drives the chloroquine product's market growth. Furthermore increasing clinical trial investigation highlighting positive therapeutic efficacy for the treatment of autoimmune diseases will further accentuate the chloroquine products market growth.
Chloroquine was developed in the early 1940s as an aminoquinolone derivative for the treatment of malaria. It is a broad-spectrum drug that is also utilized for the treatment of all strains of plasmodium infection throughout the globe and also as a prophylactic agent in the treatment of the Zika virus. It exerts its pharmacological effect by inhibiting the action of heme polymerase which eventually results in the buildup of toxic heme in the plasmodium species.
The major segments related to the chloroquine products market are:
By Clinical Application (2017–2027; US$ Mn)
Protozoan Infection
Autoimmune Diseases
Others
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment (2017–2027; US$ Mn)
North America
U.S.
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning.
Significant customers?
Segment Analysis
Protozoan infection is representing the largest market share in the clinical application segment for the chloroquine products market. As per the latest research citings provided by the World Health Organization (WHO) in 2018, approximately 228 million cases of malaria infection were reported worldwide. North Africa, South East Asia, and Amazon rain forests are the hotspot for malaria infection, where lack of awareness is associated with a high mortality rate associated with malarial infection. Amebiasis is the second largest cause of death associated with a parasitic infection, eventually causing the death of 100,000 people throughout the globe each year. Autoimmune disease is keen to record exemplary market growth in the near future on account of the growing incidence of rheumatoid arthritis worldwide. According to the latest statistics provided by the National Institute of Health (NIH), the annual incidence rate of rheumatoid arthritis is 3 cases per 10,000 people worldwide.
Hospital pharmacy is currently dominating the distribution channel segment for the chloroquine products market. The drug is associated with high degree cellular toxicity and hence precise compounding by hospital pharmacists in accordance with doctor’s prescription is mandatory to avoid fatal outcomes. Retail pharmacy is expected to register excellent market growth during the forecast period majorly due to flourishing generic drugs market in the developing regions and the ability to provide affordable medication to people residing in remote locations.
Asia Pacific is presently leading the geography segment for the chloroquine products market. The rising prevalence of protozoan infection in the South East Asia region primarily drives the market growth. Topical weather and monsoon climate provide teeming grounds for malarial and amoebiasis parasites, hence it increases the demand for chloroquine products market. Furthermore, the flourishing generic drug market further propels the chloroquine products market. Latin America holds the second-largest market share in the regional segment chiefly due to rising public health awareness resulting in early screening and treatment for protozoan infection and rising prevalence of malaria infection in the amazon rain forest. North America is anticipated to be the fastest-growing regional segment for the chloroquine products market. Affordable reimbursement scenario and supportive regulatory environment provided by the USFDA for the sale and distribution of chloroquine products drive the market growth in the region.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |